All In Biotech

Drug Trial Radar · NCT03697304

Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 (Ezabenlimab) Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy

Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 211 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

211

Actual

Start

Mar 19, 2019

Primary completion

Dec 3, 2024

Study completion Dec 3, 2024

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Oct 5, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study in adults with various types of advanced cancer. The purpose of the study is to test a medicine called BI 754091 in combination with several other cancer medicines. BI 754091 is an immunotherapy. This means it may help the immune system fight cancer. Such therapies are also called immune checkpoint inhibitors. How long the participants are in the study depends on whether they benefit from treatment and whether they experience unacceptable side effects. The participants are put into different groups. Each group receives BI 754091 in combination with another medicine. The doctors check whether the tumors shrink or disappear. The doctors also check the general health of the participants.

Conditions

  • Neoplasm Metastasis
  • Advanced Tumors
  • Metastatic Solid Tumors

Interventions

  • EzabenlimabDrug

    240 mg of ezabenlimab (BI 754091), intravenously, on Day 1 of 21-day cycles.

  • BI 754111Drug

    600 mg of BI 754111, intravenously, on Day 1 of 21-day cycles.

  • BI 836880Drug

    720 mg of BI 836880, intravenously, on Day 1 of 21-day cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Module C] Objective Response (OR)Time frame: From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 188.3 weeks.
  2. [Module C] Objective Response (OR) - Bayesian Hierarchical ModelTime frame: From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 188.3 weeks.
  3. [Module A] Objective Response (OR)Time frame: From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 152.4 weeks.
  4. [Module A] Objective Response (OR) - Bayesian Hierarchical ModelTime frame: From first drug administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy. Up to approximately 152.4 weeks.

Locations

17 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California San Diego

    La Jolla, California

  • Florida Cancer Specialists-Fort Myers-52980

    Fort Myers, Florida

  • Florida Cancer Specialists-Saint Petersburg-52979

    St. Petersburg, Florida

  • Florida Cancer Specialists-Sarasota-61670

    Tallahassee, Florida

  • Florida Cancer Specialists - East

    West Palm Beach, Florida

  • Indiana University

    Indianapolis, Indiana

  • Norton Cancer Institute

    Louisville, Kentucky

  • Oklahoma University School of Community Medicine

    Oklahoma City, Oklahoma

  • Tennessee Oncology

    Chattanooga, Tennessee

  • Tennessee Oncology, PLLC-Nashville-52568

    Nashville, Tennessee

  • Medical College Of Wisconsin

    Milwaukee, Wisconsin

  • Cross Cancer Institute (University of Alberta)

    Edmonton, Alberta, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • University College Hospital

    London, United Kingdom

  • Guy's Hospital

    London, United Kingdom

  • Sarah Cannon Research Institute, London

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.